Review anchor
High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A
CHEMBL3535
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A as ChEMBL target CHEMBL3535, mapped to UniProt O76083. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3535
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O76083
High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A matters
High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A is reviewed as High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A (UniProt O76083); High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A shows clinical signal disease relevance led by Alzheimer disease. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 3 approved drugs, 1077 compounds, and 212 assays, with lead potency reaching pChEMBL 11.0.
Protein context
High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A
High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A Sequence length is 593 aa.
Review this target as High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A, mapped to UniProt O76083. Sequence length is 593 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt O76083
Protein
Disease context
Alzheimer disease
High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A shows clinical signal disease relevance led by Alzheimer disease. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include EDELINONTRINE, OSORESNONTRINE.
Start review with Alzheimer disease because it currently carries clinical signal support. Linked drugs include EDELINONTRINE, OSORESNONTRINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Clinical signal
2 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 3 approved drugs, 1077 compounds, and 212 assays for this target. The dominant activity type is IC50. CHEMBL6066018 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL6066018 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core Engine
3 approved
pChEMBL 11.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt O76083, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why Alzheimer disease is currently treated as clinical signal support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
1077
Total Compounds
212
Total Assays
3
Approved Drugs
IC50: 1415.0, KI: 284.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL6066018
|
11.0 | Ki | — |
|
|
No preferred name
CHEMBL6042821
|
11.0 | Ki | — |
|
|
No preferred name
CHEMBL5898437
|
11.0 | Ki | — |
|
|
No preferred name
CHEMBL5823889
|
11.0 | Ki | — |
|
|
No preferred name
CHEMBL5995578
|
10.7 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
CANNABIDIOL
CHEMBL190461
|
2018 |
|
|
VARDENAFIL
CHEMBL1520
|
2003 |
Source Header